Comparative analysis of long-term results of high-tech external beam therapy and combined radiotherapy in patients with prostate cancer and high risk of progression

Background.Patients suffering from prostate cancer (PCa) with a high risk of progression need the most active treatment tactics. Escalation of radiation dose, larger daily fractions radiation therapy (including high-dose-rate interstitial brachytherapy (HDR-BT)) is a promising approach to the treatment of PCa.

Objective of the study. Comparative assessment of the long-term treatment results of patients with PCa with a poor prognosis after external beam radiotherapy (EBRT) and combined radiation therapy, depending on risk factors.

Materials and methods. 207patients who received a course EBRT and HDR-BT with EBRT (combined RT) on a radical program for the first detected PCa at the N.N. Alexandrov National Cancer Center of Belarus in 2013—2015 inclusive. All patients were belonged to the group of

high and very high risk of progression according to the criteria of the NCCN (National Comprehensive Cancer Network), all were treated with neoadjuvated hormone therapy (medical or surgical castration).

The patients were stratified into two groups: HDR-BT with EBRT and EBRT. When conducting combined RT, HDR-brachytherapy was performed in single fraction with a dose of 11.5 Gy, for EBRT it was used as a conventional fractionation (single dose of 2 Gy, total — 44 Gy) and hypofractionation (single dose of 3 Gy, total — 36 Gy). Patient that were not who not included in the combined RT protocol were treated with EBRT under a radical program in a total dose of 78—80 Gy.

Results. It was established that in the group of patients after EBRT the median survival was not achieved, the 5-year adjusted survival (AS) was 85.2 + 5.6 %. In the combined RT group, the median survival was also not reached, the 5-year-old AS was 92.2 + 5.9 %. It was found that for the patients with a Gleason score of 7 or more, a significant difference in the AS index was obtained in favor of the HDR-BT with EBRT: the 5-year AS of patients of this subgroup who were exposed to combined RT was 84.6 + 9.8 %, while after EBRT, the 5-year-old AS was 71.0 + 11.2 %. In the subgroup of patients with Gleason sum 7—10, combined RT was associated with statistically significantly better long-term results in compared with EBRT.

Conclusion.The application of the method of combined RTfor patients suffering from PCa with a high risk is characterized with satisfactory long-term treatment results.

1. Okeanov A.E., Moiseev P.I., Levin L.F. Statistics of oncological diseases in the Republic of Belarus (2004-2013). Ed. O.G. Sukonko. Minsk: N.N. Alexandrov National Cancer Center of Belarus, 2014. 382 p. (In Russ.).

2. Sukonko О G., Rolev-ich A.I., Polyakov S.L. et al. Results of radical prostatectomy at localized and regional prostate cancer. Oncologycheskiy jurnal = Journal of Oncology 2007;(1):98—108. (In Russ.).

3. Grossfeld G.D., Latini D.M., Lubeck D.P. et al. Predicting recurrence after radical prostatectomy for patients with high-risk prostate cancer. J Urol 2003;169(1):157— 63. DOI: 10.1097/01.ju.0000036470.57520.a0. PMID: 12478126.

4. Freedland S.J., Terris M.K., Csathy G.S. et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 2004;171(6):2215—20. PMID: 15126788.

5. Viani G.A., Stefano E.J., Afonso S.L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74(5):1405—18. DOI: 10.1016/j.ijrobp.2008.10.091. PMID: 19616743.

6. Storey M.R., Pollack A., Zagars G. et al. Complications from dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48(3):635—42. PMID: 11020558.

7. Chang A.J., Autio K.A., Roach M. 3rd, Scher H.I. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 2014;11(6):308—23. DOI: 10.1038/nrcli-nonc.2014.68. PMID: 24840073.

8. Froehner M., Wirth M.P. Locally advanced prostate cancer: optimal therapy in older patients. Drugs Aging 2013;(12):959—67. DOI: 10.1007/s40266-013-0123-7. PMID: 24097331.

9. Hanks G.E., Hanlon A.L., Pinover W.H. et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000;46(4):823—32. PMID: 10705002.

10. Mohler J.L., Kantoff P.W., Armstrong A.J. et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014;12(5):686—718. PMID: 24812137.

11. Demeshko P.D., Krasny S.A. Biochemical recurrence of prostate cancer after radical prostatectomy. Minsk: Printshaus, 2015. 160 p. (In Russ.).

12. Peeters S.T., Heemsbergen W.D., Koper P.C. et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990—6. DOI: 10.1200/JCO.2005.05.2530. PMID: 16648499.

13. Sveistrup J., af Rosenschold P.M., Deasy J.O. et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 2014;9(1):44. DOI: 10.1186/1748-717X-9-44. PMID: 24495815.

14. Thames H.D., Hendry J.H. Fractionation in radiotherapy. London: CRC Press, 1987. 298 p.

15. Steel G.G. Basic clinical radiobiology. London: Arnold, 2003. 280 p.

16. Tree A.C., Alexander E.J., Van As N.J. et al. Biological dose escalation and hypo-fractionation: what is there to be gained and how will it best be done? Clin Oncol 2013;25:(8):483—98. DOI: 10.1016/j.clon.2013.05.003. PMID: 23810749.

17. Spratt J.S., Meyer J.S., Spratt J.A. Rates of growth of human neoplasms: part II. J Surg Oncol 1996;61(1):68—83. PMID: 8544465.

18. Nahum A.E. The radiobiology of hypofrac-tionation. Clin Oncol (R Coll Radiol) 2015;27(5):260—9. DOI: 10.1016/j.clon.2015.02.001. PMID: 25797579.

19. Marzi S., Saracino B., Petrongari M.G. et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res 2009;28:117. DOI: 10.1186/1756-9966-28-117. PMID: 19689825.

20. Brenner D.J. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004;60(4):1013—5. DOI: 10.1016/j.ijrobp.2004.04.014. PMID: 15519768.

21. Deore S.M., Shrivastava S.K., Supe S.J. et al. Alpha/beta value and importance of dose per fraction for the late rectal and recto-sigmoid complications. Strahlenther Onkol 1993;169(9):521—6. PMID: 8211671.

22. Pellizzon A.C., Fogaroli R.C., Silva M.L. et al. High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control. Int J Clin Exp Med 2011;4(1):43—52. PMID: 21394285.